Member Info for Soupdragon78

As a reminder below is a link to a list of ongoing mid and late stage IPF trials (as of February 2023)

https://info.evaluate.com/rs/607-YGS-364/images/IPF%20article%20Feb%202023.pdf

The interesting thing about this is how few of these are inhaled and then how many have failed recently. This help open up the market for other options with a greater bank of data behind them.

From the phase 3 list we know that the following have failed.

Roche - PRM 151

Fibrogen - Pamrevlumab

So this leaves only two IPF treatments in phase 3.

In the phase 2 the following have failed/difficulties.

Pliant - Bexotegrast - reported as being taken to phase 2b but showing lesser efficacy than in earlier tests.

Algernon Pharma - NP-120 - Phase 2b for IPF 'postponed' with no further date, only being tested for chronic cough now.

Bristol Myers - BMS-986278 - Phase 2 halted after three participants developed cholecystitis, an inflammation of the gallbladder. Also showing indications of liver inflammation

Calm down dear… you’re getting quite worked up for something you aren’t invested in.

That’s good then as the company won’t be paying for phase 1.

Correction, the £465k figure was the start of the period not the end.

So March was £260k, meaning approx £390k before outgoings.

See... its not hard to admit when you make a mistake.

Anyway, at end of March the cash position was £465k

Since then they have received £70k from placing and circa £60k from Lanstead to date.

So approx £595k in cash prior to outgoings.

They can claim cash payment of 33% of R&D costs from the government. Which would be circa £150k cash.

Plus they have a further £85k due when warrants are exercised.

Chill the beans.

Someone’s grumpy today, must be missing out on todays strikes.

Lol!

The fact that someone thinks this is invoiced is laughable.

Sometimes it’s better just to admit when you are wrong.

*sighs* Those at the back need to pay attention.

“The First Subscription proceeds of £330,000 will be pledged to Lanstead under a Sharing … …. monthly settlements (subject to adjustment upwards or downwards) to the Company over four months, as detailed below.”

“Admission and dealings in the First Subscription Shares and the First Value Payment Shares is expected to commence at 8.00am on 17 December 2021.”

“The monthly settlement amounts for the First Sharing Agreement are structured to commence approximately three months following Admission of the First Subscription Shares.”

“The second Sharing Agreement (the "Second Sharing Agreement") provides that the Company, in return for pledging the £1,320,000 proceeds from the Second Subscription Shares, will receive 16 equal monthly settlement amounts as measured against the Benchmark Price. The monthly settlement amounts for the Second Sharing Agreement are structured to commence one month following the receipt of the final settlement due under the First Sharing Agreement.”

So 4 payments to commence 3 months after first tranche are admitted.

1st tranche admitted to market 17th December. 2021

First payment Mid March 2022

Second tranche commences July 2022 for 16 months.

Second tranche ends October 2023.

As the saying goes....

Those who can do, those who can't teach.

For those who have trouble reading.

“ In December 2021 the Company entered into a Sharing Agreement with Lanstead, split into two tranches of new shares issued with payments to be received over a 20-month period from March 2022 to October 2023.”

Interesting on the fibroids in mice, but unfortunately not covered in NFX patent.

Depends on how much competition there is.

Look at NCYT buying YGEN the other day for £16m, three years ago it was valued at £150m+

If only one party is interested then they will play low ball.

Nothing new there, that study has been cited by NFX since it came out.

Its cited in the investor presentations from April 2021 on the website.

Also to note, Insilico's drug was developed through pre-clinical as a combination therapy with the SoC.

Interesting paragraph at the bottom of this article on Insilico's phase II trial for their IPF treatment.

Identifying the move away from the USA in terms of likely future patient geography.

'IPF landscape

IPF is the most common subtype of idiopathic interstitial pneumonias (IIPs), characterised by damaged and scarred lung tissue. A GlobalData competitive landscape report estimates that in 2028 the highest diagnosed prevalent cases of IPF will be in China and India.'

https://www.clinicaltrialsarena.com/news/insilico-medicine-ins018055-ai/

Good to hear your all just investors waiting for a deal teajay, and definitely no one saying that there needs to be PR to tantalise people into buying.

Thanks trans, although someone saying something is not on the table doesn’t necessarily mean it couldn’t be in future.

Trans, what reason did they give for not being interrested?

Hale, would Kissei buy if the Japanese patent wasn't in place?

Hikma is classed as mid-size.

UK based with an mcap of circa £4bn, annual revenues of £2.5bn.

Whether they are into IPF treatment, who knows?

"Roche has form in making IPF acquisitions, picking up Esbriet’s originator Intermune in 2014 for $8.3bn, and zinpentraxin alfa’s maker Promedior for $390m up front five years later. If it does want to strike another deal in IPF, there are plenty of targets to choose from."

Bit of further digging around in the IPF space.

Interesting that AstraZeneca are pushing the AI route for novel IPF treatments. They have already discovered 3 new IPF leads through their collaboration with Cambridge based BenevolentAI and have taken one of these to pre-clinical.

https://www.benevolent.com/news-and-media/press-releases-and-in-media/new-preclinical-data-ai-generated-target-identified-benevolentai-and-astrazeneca-collaboration-presented-ats-2023/

I personally don't see NXP002 as a fit for AZ, given they are investing heavily in their own routes already. More likely a mid size outfit looking to break into a space.

Boeringher recently had FDA approval on their IPF treatment so seem preoccupied with that.